Celon Pharma is currently working on nine innovative projects

… Ketamine for treatment-resistant depression is likely to be the first new drug from Celon Pharma to reach the market. This should happen in 2021-2022, depending on whether the regulator accepts the results of six-month studies as sufficient or requires longer, 12-month or 18-month trials.

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.